Skip to main content
NASDAQ:VIVO

Meridian Bioscience Competitors

$18.01
-0.60 (-3.22 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.98
$18.72
50-Day Range
$18.51
$28.32
52-Week Range
$12.98
$30.65
Volume545,782 shs
Average Volume753,290 shs
Market Capitalization$780.37 million
P/E Ratio16.68
Dividend YieldN/A
Beta0.59

Competitors

Meridian Bioscience (NASDAQ:VIVO) Vs. ALGN, WST, COO, XRAY, STAA, and QDEL

Should you be buying VIVO stock or one of its competitors? Companies in the sub-industry of "health care supplies" are considered alternatives and competitors to Meridian Bioscience, including Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), STAAR Surgical (STAA), and Quidel (QDEL).

Align Technology (NASDAQ:ALGN) and Meridian Bioscience (NASDAQ:VIVO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for Align Technology and Meridian Bioscience, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Align Technology111002.75
Meridian Bioscience00203.00

Align Technology presently has a consensus target price of $627.0909, suggesting a potential upside of 14.30%. Meridian Bioscience has a consensus target price of $32.00, suggesting a potential upside of 77.68%. Given Meridian Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Meridian Bioscience is more favorable than Align Technology.

Earnings and Valuation

This table compares Align Technology and Meridian Bioscience's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Align Technology$2.41 billion18.04$442.78 million$4.96110.61
Meridian Bioscience$253.67 million3.08$46.19 million$1.0716.83

Align Technology has higher revenue and earnings than Meridian Bioscience. Meridian Bioscience is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Align Technology has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500. Comparatively, Meridian Bioscience has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.

Institutional & Insider Ownership

85.8% of Align Technology shares are held by institutional investors. Comparatively, 88.3% of Meridian Bioscience shares are held by institutional investors. 1.2% of Align Technology shares are held by insiders. Comparatively, 2.0% of Meridian Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Align Technology and Meridian Bioscience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Align Technology76.00%68.99%46.64%
Meridian Bioscience18.21%21.06%12.55%

Summary

Align Technology beats Meridian Bioscience on 10 of the 14 factors compared between the two stocks.

Meridian Bioscience (NASDAQ:VIVO) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Volatility and Risk

Meridian Bioscience has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Profitability

This table compares Meridian Bioscience and West Pharmaceutical Services' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Meridian Bioscience18.21%21.06%12.55%
West Pharmaceutical Services14.69%19.01%12.78%

Institutional & Insider Ownership

88.3% of Meridian Bioscience shares are owned by institutional investors. Comparatively, 92.6% of West Pharmaceutical Services shares are owned by institutional investors. 2.0% of Meridian Bioscience shares are owned by insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Meridian Bioscience and West Pharmaceutical Services' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meridian Bioscience$253.67 million3.08$46.19 million$1.0716.83
West Pharmaceutical Services$1.84 billion13.03$241.70 million$3.24100.25

West Pharmaceutical Services has higher revenue and earnings than Meridian Bioscience. Meridian Bioscience is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Meridian Bioscience and West Pharmaceutical Services, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Meridian Bioscience00203.00
West Pharmaceutical Services01202.67

Meridian Bioscience currently has a consensus target price of $32.00, suggesting a potential upside of 77.68%. West Pharmaceutical Services has a consensus target price of $310.00, suggesting a potential downside of 4.56%. Given Meridian Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Meridian Bioscience is more favorable than West Pharmaceutical Services.

Summary

West Pharmaceutical Services beats Meridian Bioscience on 8 of the 13 factors compared between the two stocks.

Meridian Bioscience (NASDAQ:VIVO) and The Cooper Companies (NYSE:COO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Insider and Institutional Ownership

88.3% of Meridian Bioscience shares are held by institutional investors. Comparatively, 95.8% of The Cooper Companies shares are held by institutional investors. 2.0% of Meridian Bioscience shares are held by insiders. Comparatively, 1.4% of The Cooper Companies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and price targets for Meridian Bioscience and The Cooper Companies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Meridian Bioscience00203.00
The Cooper Companies04702.64

Meridian Bioscience currently has a consensus target price of $32.00, suggesting a potential upside of 77.68%. The Cooper Companies has a consensus target price of $385.50, suggesting a potential upside of 0.20%. Given Meridian Bioscience's stronger consensus rating and higher possible upside, equities research analysts plainly believe Meridian Bioscience is more favorable than The Cooper Companies.

Profitability

This table compares Meridian Bioscience and The Cooper Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Meridian Bioscience18.21%21.06%12.55%
The Cooper Companies9.81%12.79%7.20%

Valuation and Earnings

This table compares Meridian Bioscience and The Cooper Companies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meridian Bioscience$253.67 million3.08$46.19 million$1.0716.83
The Cooper Companies$2.43 billion7.78$238.40 million$9.6439.91

The Cooper Companies has higher revenue and earnings than Meridian Bioscience. Meridian Bioscience is trading at a lower price-to-earnings ratio than The Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Meridian Bioscience has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, The Cooper Companies has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Summary

The Cooper Companies beats Meridian Bioscience on 8 of the 14 factors compared between the two stocks.

DENTSPLY SIRONA (NASDAQ:XRAY) and Meridian Bioscience (NASDAQ:VIVO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Profitability

This table compares DENTSPLY SIRONA and Meridian Bioscience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DENTSPLY SIRONA-1.40%7.13%4.13%
Meridian Bioscience18.21%21.06%12.55%

Insider and Institutional Ownership

96.0% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 88.3% of Meridian Bioscience shares are owned by institutional investors. 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Comparatively, 2.0% of Meridian Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for DENTSPLY SIRONA and Meridian Bioscience, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DENTSPLY SIRONA14602.45
Meridian Bioscience00203.00

DENTSPLY SIRONA currently has a consensus target price of $60.00, indicating a potential downside of 8.68%. Meridian Bioscience has a consensus target price of $32.00, indicating a potential upside of 77.68%. Given Meridian Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Meridian Bioscience is more favorable than DENTSPLY SIRONA.

Earnings & Valuation

This table compares DENTSPLY SIRONA and Meridian Bioscience's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DENTSPLY SIRONA$4.03 billion3.56$262.90 million$2.4526.82
Meridian Bioscience$253.67 million3.08$46.19 million$1.0716.83

DENTSPLY SIRONA has higher revenue and earnings than Meridian Bioscience. Meridian Bioscience is trading at a lower price-to-earnings ratio than DENTSPLY SIRONA, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

DENTSPLY SIRONA has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Meridian Bioscience has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.

Meridian Bioscience (NASDAQ:VIVO) and STAAR Surgical (NASDAQ:STAA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Profitability

This table compares Meridian Bioscience and STAAR Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Meridian Bioscience18.21%21.06%12.55%
STAAR Surgical5.73%8.99%7.12%

Valuation and Earnings

This table compares Meridian Bioscience and STAAR Surgical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meridian Bioscience$253.67 million3.08$46.19 million$1.0716.83
STAAR Surgical$150.18 million34.59$14.05 million$0.46240.84

Meridian Bioscience has higher revenue and earnings than STAAR Surgical. Meridian Bioscience is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Meridian Bioscience and STAAR Surgical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Meridian Bioscience00203.00
STAAR Surgical03302.50

Meridian Bioscience currently has a consensus target price of $32.00, indicating a potential upside of 77.68%. STAAR Surgical has a consensus target price of $78.40, indicating a potential downside of 29.23%. Given Meridian Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Meridian Bioscience is more favorable than STAAR Surgical.

Volatility and Risk

Meridian Bioscience has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Insider & Institutional Ownership

88.3% of Meridian Bioscience shares are owned by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are owned by institutional investors. 2.0% of Meridian Bioscience shares are owned by company insiders. Comparatively, 3.9% of STAAR Surgical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Meridian Bioscience beats STAAR Surgical on 9 of the 14 factors compared between the two stocks.

Quidel (NASDAQ:QDEL) and Meridian Bioscience (NASDAQ:VIVO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Volatility and Risk

Quidel has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, Meridian Bioscience has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Institutional and Insider Ownership

84.0% of Quidel shares are owned by institutional investors. Comparatively, 88.3% of Meridian Bioscience shares are owned by institutional investors. 14.1% of Quidel shares are owned by insiders. Comparatively, 2.0% of Meridian Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Quidel and Meridian Bioscience, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quidel10302.50
Meridian Bioscience00203.00

Quidel currently has a consensus price target of $182.75, suggesting a potential upside of 52.37%. Meridian Bioscience has a consensus price target of $32.00, suggesting a potential upside of 77.68%. Given Meridian Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Meridian Bioscience is more favorable than Quidel.

Profitability

This table compares Quidel and Meridian Bioscience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quidel36.91%63.31%40.55%
Meridian Bioscience18.21%21.06%12.55%

Valuation & Earnings

This table compares Quidel and Meridian Bioscience's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quidel$534.89 million9.54$72.92 million$2.7343.93
Meridian Bioscience$253.67 million3.08$46.19 million$1.0716.83

Quidel has higher revenue and earnings than Meridian Bioscience. Meridian Bioscience is trading at a lower price-to-earnings ratio than Quidel, indicating that it is currently the more affordable of the two stocks.

Summary

Quidel beats Meridian Bioscience on 9 of the 14 factors compared between the two stocks.


Meridian Bioscience Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Align Technology logo
ALGN
Align Technology
2.1$548.64-3.2%$43.42 billion$2.41 billion24.96Insider Selling
Gap Down
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$324.80-3.2%$23.98 billion$1.84 billion85.70Insider Selling
The Cooper Companies logo
COO
The Cooper Companies
1.9$384.72-0.9%$18.91 billion$2.43 billion79.98
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$65.70-1.7%$14.34 billion$4.03 billion-285.65Earnings Announcement
Analyst Revision
STAAR Surgical logo
STAA
STAAR Surgical
1.4$110.79-2.0%$5.20 billion$150.18 million583.11Analyst Report
Insider Selling
News Coverage
Gap Down
Quidel logo
QDEL
Quidel
2.4$119.94-4.4%$5.10 billion$534.89 million14.08
Neogen logo
NEOG
Neogen
1.2$89.56-2.7%$4.79 billion$418.17 million78.56
ICU Medical logo
ICUI
ICU Medical
1.7$190.83-3.0%$4.05 billion$1.27 billion50.48Earnings Announcement
Insider Selling
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.7$59.10-4.6%$3.31 billion$994.85 million-111.51Insider Selling
Haemonetics logo
HAE
Haemonetics
2.1$59.83-0.3%$3.04 billion$988.48 million28.90
Atrion logo
ATRI
Atrion
1.1$596.61-3.4%$1.09 billion$155.07 million33.61
Cerus logo
CERS
Cerus
1.7$5.57-1.1%$953.43 million$74.65 million-14.28Analyst Revision
Gap Down
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$9.28-2.9%$667.79 million$154.60 million-40.35Analyst Downgrade
Analyst Revision
Antares Pharma logo
ATRS
Antares Pharma
1.8$3.77-2.7%$636.37 million$123.86 million62.84Analyst Report
Analyst Revision
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$42.20-0.9%$607.30 million$114.51 million-89.79
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.34-2.0%$318.44 million$46.90 million27.55Dividend Announcement
This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.